Clinical Trials Logo

Recurrent Gastrointestinal Carcinoid Tumor clinical trials

View clinical trials related to Recurrent Gastrointestinal Carcinoid Tumor.

Filter by:

NCT ID: NCT02259725 Recruiting - Insulinoma Clinical Trials

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Start date: August 16, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01155258 Completed - Clinical trials for Stage IV Breast Cancer

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Start date: June 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with vinorelbine ditartrate may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving temsirolimus and vinorelbine ditartrate together in treating patients with unresectable or metastatic solid tumors.

NCT ID: NCT00655655 Active, not recruiting - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Start date: December 2004
Phase: Phase 1
Study type: Interventional

RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus and vatalanib in treating patients with advanced solid tumors.

NCT ID: NCT00397384 Completed - Clinical trials for Stage IV Non-small Cell Lung Cancer

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

Start date: January 2007
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck cancer, non-small cell lung cancer, or colorectal cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Erlotinib hydrochloride and cetuximab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving erlotinib hydrochloride together with cetuximab may kill more tumor cells.

NCT ID: NCT00131911 Completed - Clinical trials for Neuroendocrine Tumor

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Start date: June 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00093782 Completed - Clinical trials for Recurrent Islet Cell Carcinoma

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Start date: December 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well CCI-779 works in treating patients with progressive metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00087191 Terminated - Clinical trials for Fallopian Tube Cancer

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

Start date: May 2004
Phase: N/A
Study type: Interventional

This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer. EF5 may be effective in measuring oxygen in tumor tissue. Photosensitizing drugs such as motexafin lutetium are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. Knowing the level of oxygen in tumor tissue and the level of motexafin lutetium absorbed by tumors and normal tissue may help predict the effectiveness of anticancer therapy

NCT ID: NCT00084461 Terminated - Insulinoma Clinical Trials

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Start date: March 2004
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of romidepsin in treating patients who have locally advanced or metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00075439 Completed - Insulinoma Clinical Trials

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Start date: December 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

NCT ID: NCT00055809 Completed - Clinical trials for Recurrent Gastrointestinal Carcinoid Tumor

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Start date: January 2003
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is to see if combining bevacizumab with PEG-interferon alfa-2b works in treating patients who have metastatic or unresectable carcinoid tumors. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. PEG-interferon alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. Combining bevacizumab with PEG-interferon alfa-2b may kill more cancer cells